Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Policy / Regulatory

NMPA Releases Draft Implementation Rules for the National Key R&D Program – Public Comment Open Through 12 Sept 2026

Fineline Cube Aug 14, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes

Fineline Cube Aug 17, 2026
Company Drug

CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine

Fineline Cube Aug 17, 2026
Company Deals

Inkon Life Technology Partners with United Imaging to Establish Advanced Medical Centers and Digital Platform

Fineline Cube Jun 24, 2024

Inkon Life Technology Co., Ltd. (SHE: 300143), a Shenzhen-based service provider specializing in stereotactic radiotherapy...

Company Deals

METiS Therapeutics Secures USD 100 Million in Series C Financing to Advance AI Drug Delivery

Fineline Cube Jun 24, 2024

METiS Therapeutics, a biopharmaceutical company based in Cambridge, Massachusetts, has secured USD 100 million in...

Company Drug

Qilu Pharmaceutical’s Generic Version of Vyndaqel Receives NMPA Marketing Approval

Fineline Cube Jun 21, 2024

The National Medical Products Administration (NMPA) has granted marketing approval to Qilu Pharmaceutical’s generic version...

Company Deals Medical Device

Jiangsu Yuyue Medical Teams Up with China Unicom for Digital Healthcare Innovation

Fineline Cube Jun 21, 2024

Shanghai-based Jiangsu Yuyue Medical Equipment Inc. (SHE: 002223) has announced a strategic partnership with China...

Company Deals

Ascentage Pharma’s THDBH120 Receives NMPA Approval for Phase Ib Clinical Trial

Fineline Cube Jun 21, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...

Company Deals Hospital

Shineco Inc. Acquires 80% Stake in ‘Internet+Medical Care’ Platform Meitong Tech for USD 20 Million

Fineline Cube Jun 21, 2024

Shineco Inc. (NASDAQ: SISI), a U.S.-based company, has signed an investment agreement with Beijing Dongfang...

Company Drug

Zhangzhou Pien Tze Huang’s PZH2113 Receives NMPA Clinical Trial Approval for Lymphoma Treatment

Fineline Cube Jun 21, 2024

Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (SHA: 600436), a renowned traditional Chinese medicine (TCM)...

Company Drug

Tonghua Dongbao Pharmaceuticals’ THDBH120 Receives NMPA Approval for Phase II Clinical Trial

Fineline Cube Jun 21, 2024

Tonghua Dongbao Pharmaceuticals (SHA: 600867), based in China, has announced that the National Medical Products...

Company Deals

DK Medical Technology Secures ‘Hundreds of Millions’ in Series E Financing for Expansion

Fineline Cube Jun 21, 2024

DK Medical Technology Co. Ltd., a Suzhou-based developer of vascular intervention balloon products, has reportedly...

Company Deals

Shanghai Fudan-Zhangjiang and Hanhui Pharmaceutical End Marketing Deal for Libaoduo

Fineline Cube Jun 21, 2024

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505), a Chinese biopharmaceutical company, has reached...

Company Drug

Luye Pharma’s Once-Weekly Parkinson’s Disease Treatment Receives NMPA Approval

Fineline Cube Jun 21, 2024

Luye Pharma Group (HKG: 2186) has announced that it has received marketing approval from the...

Company Drug

Fudan-Zhangjiang Bio-Pharmaceutical Advances Aminolevulinic Acid Study for Glioma Visualization

Fineline Cube Jun 21, 2024

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505) has announced that the first subject...

Company Deals

Novartis Moves Toward Full Ownership of MorphoSys with Shareholder Squeeze-Out

Fineline Cube Jun 21, 2024

Novartis AG (NYSE: NVS), the Swiss pharmaceutical giant, is proceeding to fully acquire MorphoSys AG...

Policy / Regulatory

China Expands Controlled Substances Catalogue to Include Three Additional Substances

Fineline Cube Jun 20, 2024

The Ministry of Public Security, National Health Commission, and National Medical Products Administration in China...

Company Drug

Dizal Pharmaceutical’s Golidocitinib Wins NMPA Approval for Relapsed/Refractory PTCL

Fineline Cube Jun 20, 2024

Dizal Pharmaceutical Co., Ltd (SHA: 688192), a spin-off from AstraZeneca China established in 2017, has...

Company Deals

Shanghai Fosun Pharmaceutical Sells Stake in Gland Pharma for USD 211 Million

Fineline Cube Jun 20, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the sale of...

Company

Jiuzhou Pharmaceutical Shuts Down Two Subsidiaries to Streamline Operations

Fineline Cube Jun 20, 2024

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a pharmaceutical company based in China, has announced...

Company Drug

Keymed Biosciences’ CM313 Shows Promise in Treating Immune Thrombocytopenia, NEJM Study Says

Fineline Cube Jun 20, 2024

Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has published results from...

Company Deals

Xencor Reclaims Rights to Plamotamab After Janssen Halts Development

Fineline Cube Jun 20, 2024

Xencor Inc. (NASDAQ: XNCR), a U.S.-based biotechnology company, has announced that Johnson & Johnson (J&J,...

Company Drug

AbbVie’s Skyrizi Secures FDA Approval for Ulcerative Colitis, Expands Treatment Portfolio

Fineline Cube Jun 20, 2024

AbbVie (NYSE: ABBV) has announced that the U.S. Food and Drug Administration (FDA) has approved...

Posts pagination

1 … 385 386 387 … 709

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
  • CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine
  • Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑002, a Brain‑Penetrant BTK PROTAC for B‑Cell Non‑Hodgkin Lymphoma
  • Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets
  • Shanghai Ark Biopharmaceutical Wins FDA Clearance for Ziresovir Phase II Trials in Severe Pediatric RSV
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes

Company Drug

CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine

Company Drug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑002, a Brain‑Penetrant BTK PROTAC for B‑Cell Non‑Hodgkin Lymphoma

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.